尚荣医疗
(002551)
| 流通市值：22.73亿 | | | 总市值：31.45亿 |
| 流通股本：6.11亿 | | | 总股本：8.45亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 279,741,529.44 | 1,448,206,268.39 | 1,002,639,030.84 | 631,461,882.24 |
| 营业收入 | 279,741,529.44 | 1,448,206,268.39 | 1,002,639,030.84 | 631,461,882.24 |
| 二、营业总成本 | 283,907,062.28 | 1,385,050,001.21 | 990,946,064.65 | 625,939,925.56 |
| 营业成本 | 237,019,686.94 | 1,188,953,686.35 | 843,830,113.81 | 535,000,227.83 |
| 税金及附加 | 5,724,769.63 | 22,465,222.76 | 15,273,208.2 | 9,912,287.05 |
| 销售费用 | 3,821,439.95 | 16,073,186.74 | 11,448,990.8 | 7,397,845.43 |
| 管理费用 | 33,921,138.26 | 132,993,791.04 | 107,863,929.34 | 66,929,219.47 |
| 研发费用 | 10,064,345.68 | 40,783,991.67 | 29,181,706.49 | 17,331,525.15 |
| 财务费用 | -6,644,318.18 | -16,219,877.35 | -16,651,883.99 | -10,631,179.37 |
| 其中:利息费用 | 968,478.8 | 5,828,053.65 | 1,788,712.36 | 979,507.5 |
| 其中:利息收入 | 1,477,585.18 | 10,764,801.48 | 7,712,636.19 | 4,936,232.11 |
| 加:公允价值变动收益 | -919,641.25 | 1,322,766.63 | 816,281.21 | 51,081.77 |
| 加:投资收益 | 2,964,577.49 | 2,701,178.47 | 1,476,489.13 | 4,075,054 |
| 资产处置收益 | 3,106.5 | 124,830.39 | 79,580.87 | 80,028.22 |
| 资产减值损失(新) | 9,916.72 | -9,154,823.65 | 1,552,679.83 | 1,488,891.34 |
| 信用减值损失(新) | 25,797,294.22 | -29,835,989.98 | -7,580,371.28 | 476,383.78 |
| 其他收益 | 900,757.74 | 5,223,044.58 | 2,977,073.61 | 1,780,436.65 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 24,590,478.58 | 33,537,273.62 | 11,014,699.56 | 13,473,832.44 |
| 加:营业外收入 | 187,926.28 | 6,220,965.74 | 10,077,979.72 | 10,006,400.69 |
| 减:营业外支出 | 242,222.25 | 6,154,699.75 | 537,576.14 | 215,179.37 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 24,536,182.61 | 33,603,539.61 | 20,555,103.14 | 23,265,053.76 |
| 减:所得税费用 | 7,489,988.41 | 7,691,020.41 | 1,960,864.39 | 4,592,078.07 |
| 六、净利润 | 17,046,194.2 | 25,912,519.2 | 18,594,238.75 | 18,672,975.69 |
| 持续经营净利润 | 17,046,194.2 | 25,912,519.2 | 18,594,238.75 | 18,672,975.69 |
| 归属于母公司股东的净利润 | 13,964,187.65 | 22,281,952.68 | 14,727,598.37 | 14,026,648.44 |
| 少数股东损益 | 3,082,006.55 | 3,630,566.52 | 3,866,640.38 | 4,646,327.25 |
| (一)基本每股收益 | 0.02 | 0.03 | 0.02 | 0.02 |
| (二)稀释每股收益 | 0.02 | 0.03 | 0.02 | 0.02 |
| 八、其他综合收益 | -2,862,041.24 | 5,093,558.79 | -2,006,874.66 | 1,838,850.17 |
| 归属于母公司股东的其他综合收益 | -4,001,937.53 | 5,569,518.82 | -4,584,700.94 | 1,767,440.55 |
| 九、综合收益总额 | 14,184,152.96 | 31,006,077.99 | 16,587,364.09 | 20,511,825.86 |
| 归属于母公司股东的综合收益总额 | 9,962,250.12 | 27,851,471.5 | 10,142,897.43 | 15,794,088.99 |
| 归属于少数股东的综合收益总额 | 4,221,902.84 | 3,154,606.49 | 6,444,466.66 | 4,717,736.87 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-29 | 2024-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |